NCT06518382 2026-04-15
Tumor-microenvironment Spatial Interaction to Identify Markers of Resistance to Therapy in HER2+ Breast Cancer Patients
IRCCS Ospedale San Raffaele
Recruiting
Clinical Trials
25 trialsNCT07281001 2025-12-15
Traderrus
Blokhin's Russian Cancer Research Center
Phase NA Recruiting
NCT05982678 2025-11-26
ANISE
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT06123988 2025-08-06
FastER
University of Miami
Phase NA Recruiting
NCT05705401 2025-08-03
HERO
NRG Oncology
Phase 3 Recruiting
NCT06992882 2025-07-18
A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)
Fudan University
Phase 3 Recruiting
NCT04332588 2025-05-29
Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
University of Alabama at Birmingham
Phase 1 Recruiting
NCT05955170 2025-03-27
TUC-TOC
Institut Curie
Phase 2 Recruiting
NCT06832904 2025-02-18
Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT05306041 2025-02-17
GeparPiPPa
GBG Forschungs GmbH
Phase 2 Recruiting
NCT06754059 2025-01-01
Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC
Fujian Medical University Union Hospital
Recruiting
NCT06722599 2024-12-09
LRNacHER2
Peking University People's Hospital
Recruiting
NCT06722612 2024-12-09
TaxCbHER2
Peking University People's Hospital
Recruiting
NCT06711055 2024-12-02
TaxHER
Peking University People's Hospital
Recruiting
NCT06711068 2024-12-02
TaxDHER2
Peking University People's Hospital
Recruiting
NCT06700369 2024-11-25
NacHER2
Peking University People's Hospital
Recruiting
NCT06693024 2024-11-20
NeraHER2
Peking University People's Hospital
Recruiting
NCT06693037 2024-11-20
nonPHER
Peking University People's Hospital
Recruiting
NCT05635487 2024-07-05
A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
Shengjing Hospital
Phase 2 Recruiting
NCT06330012 2024-03-26
The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
Samsung Medical Center
Phase NA Recruiting
NCT06217185 2024-02-28
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
Hebei Medical University Fourth Hospital
Phase 4 Recruiting
NCT05834764 2023-04-28
Pyrotinib in Women With High-risk in Early Stage Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT04638725 2022-08-03
SIGHER
Institut de cancérologie Strasbourg Europe
Recruiting
NCT04481932 2020-07-22
Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer
Peking University
Phase 2 Recruiting
NCT04281641 2020-05-04
PHC-BC
Fudan University
Phase NA Recruiting